Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
This grant supports researchers in analyzing existing data to understand cancer risk and related outcomes, aiming to address key scientific questions in cancer research.
Funder: National Institutes of Health
Due Dates: June 16, 2025 (New) | July 16, 2025 (Renewal/Resubmission/Revision) | October 16, 2025 (New) | November 16, 2025 (Renewal/Resubmission/Revision) | February 16, 2026 (New) | March 16, 2026 (Renewal/Resubmission/Revision) | June 16, 2026 (New) | July 16, 2026 (Renewal/Resubmission/Revision)
Funding Amounts: Up to $275,000 direct costs over 2 years; no more than $200,000 in any single year; max project period 2 years.
Summary: Supports secondary analysis and integration of existing data to elucidate cancer risk and related outcomes; clinical trials are not allowed.
Key Information: No new data collection except up to 10% of budget for validation; foreign and domestic applicants eligible; limited to non-clinical trial research.
Description
This opportunity, offered by the National Cancer Institute (NCI) and other NIH institutes, funds exploratory/developmental (R21) projects that conduct secondary analysis and integration of existing datasets to advance understanding of cancer risk and related outcomes. The initiative aims to address key scientific questions in cancer research by leveraging and innovatively analyzing existing clinical, environmental, surveillance, health services, behavioral, lifestyle, genomic, and molecular data. Projects may propose new research aims, advanced analytical methods, or novel integration of datasets, but must not include clinical trials.
